Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by ARRon Aug 29, 2012 3:39pm
328 Views
Post# 20275946

Munich Conference

Munich Conference

Scientists at theconference in Munich have disputred theories that dark chocolate and red wine are good for the heart.

"Scientists claim there is no proof that chocolate and red wine cut heart disease – despite millions hoping they do.

 The mechanisms by which they could make a difference have still to be explained, according to heart specialists.

 The evidence that dark chocolate protects the heart remains elusive, even though a recent study showed a 37 per cent cut in risk for those eating a square a day. 

This was only a 'sign', however, and not proof because the study was flawed, said Steffen Desch from the University of Leipzig Heart Centre in Germany.

 He said a more conclusive trial could be difficult because the real thing would have to be tested against a 'dummy' substance that looked and tasted like chocolate.

 Some small studies have claimed that chocolate lowers blood pressure and reduces inflammation in the body. But Dr Desch is unconvinced.

 'Despite the studies I couldn't yet recommend dark chocolate as a prevention or treatment in cardiovascular disease,' he said.

 'There's no strong evidence of a benefit and no clear explanation of an effective mechanism.' The calories contained in chocolate are likely to offset any protection to the heart, he added.

His reservations came as Dutch researchers dampened down speculation about the benefits of red wine on the heart.

They have tested resveratrol, which is found in the skin of red grapes and is believed to have a range of life-enhancing properties.

Eric Sijbrands, of Erasmus University Medical Centre in Rotterdam, led a series of studies which failed to replicate the findings of heart benefits from taking resveratrol.

 Using it in capsules for four weeks did not lower blood pressure in patients with hypertension, he said. 'Certainly I would never actively prescribe red wine for a heart condition and, even if I was asked about it, I would be cautious,' he added.

 If red wine does work, the explanation is likely to be 'complex', he said. Any benefit from moderate consumption is likely to be small and outweighed by the adverse effects of drinking too much.

 The scientists were speaking at the European Congress of Cardiology in Munich yesterday."

 

 

Bullboard Posts